<DOC>
	<DOCNO>NCT00296036</DOCNO>
	<brief_summary>RATIONALE : Pyridoxine ( vitamin B6 ) topical urea/lactic acid-based cream may prevent lessen hand-foot syndrome cause chemotherapy . It yet know whether give pyridoxine without topical urea/lactic acid-based cream effective topical urea/lactic acid-based cream alone placebo prevent hand-foot syndrome . PURPOSE : This randomized phase III trial study pyridoxine topical urea/lactic acid-based cream see well work compare give pyridoxine together placebo , give topical urea/lactic acid-based cream together placebo , give two placebos prevent hand-foot syndrome patient receive capecitabine breast cancer cancer .</brief_summary>
	<brief_title>Pyridoxine Topical Urea/Lactic Acid-Based Cream Preventing Hand-Foot Syndrome Patients Receiving Capecitabine Breast Cancer Other Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine whether prophylactic use topical urea/lactic acid cream decrease incidence/severity capecitabine-caused palmar-plantar erythrodysesthesia patient receive capecitabine breast and/or cancer . - Evaluate potential toxicity cream . - Determine whether prophylactic use vitamin B6 decrease incidence and/or severity capecitabine-caused palmar-plantar erythrodysesthesia . - Evaluate potential toxicity vitamin B6 . - Determine whether prophylactic use topical urea/lactic acid cream combination vitamin B6 decrease incidence and/or severity capecitabine cause palmar-plantar erythrodysesthesia . OUTLINE : This randomize , double-blind , placebo-controlled study . Patients stratify accord age ( &lt; 50 year old vs 50-60 year old v &gt; 60 year old ) , sex , capecitabine dose level ( 2000 mg/day v 2500 mg/day ) , cancer type ( breast v ) , mode therapy ( adjuvant [ include neo-adjuvant ] therapy v metastatic disease ) . Patients randomize 1 6 treatment arm ( treatment arm I-IV close accrual 10/24/007 ) . - Arm I ( close accrual 10/24/2007 ) : Patients receive topical urea/lactic acid-based cream apply palm sol twice daily oral pyridoxine daily day 1-21 . - Arm II ( close accrual 10/24/2007 ) : Patients receive topical urea/lactic acid-based cream arm I ( close accrual 10/24/2007 ) oral placebo daily day 1-21 . - Arm III ( close accrual 10/24/2007 ) : Patients receive placebo cream apply palm sol twice daily pyridoxine arm I ( close accrual 10/24/2007 ) . - Arm IV ( close accrual 10/24/2007 ) : Patients receive placebo cream arm III oral placebo arm II ( close accrual 10/24/2007 ) . - Arm V : Patients receive topical urea/lactic acid-based cream apply palm sol twice daily day 1-21 . - Arm VI : Patients receive placebo cream apply palm sol twice daily day 1-21 . In arm , treatment repeat every 21 day 4 course absence disease progression unacceptable toxicity .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Pyridoxine</mesh_term>
	<mesh_term>Vitamin B 6</mesh_term>
	<mesh_term>Pyridoxal</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm breast and/or cancer Undergoing first treatment capecitabine adjuvant ( include neoadjuvant ) therapy OR metastatic disease Receiving dose capecitabine either 2,000 mg/day ( 1,000 mg twice daily ) OR 2,500 mg/day 14 day 4 course therapy 3 week ( +/ 3 day ) interval Hormonereceptor status specify PATIENT CHARACTERISTICS : Male female Menopausal status specify No history allergy ureacontaining cream No preexisting neuropathy ≥ grade 2 No dermatologic condition , , opinion physician , may affect hand foot may complicate evaluation study treatment PRIOR CONCURRENT THERAPY : No concurrent agent function prevent palmarplantar erythrodysesthesia cause capecitabine topical agent hand foot indication ( e.g. , dryness ) No concurrent vitamin B6 &gt; 50 mg/day No concurrent plan use overthecounter product contain urea lactic acid , include follow : Aqua Care® Medicated Calamine^® lotion ( 0.3 % ) Coppertone^® Waterproof Ultra Protection Sunblock Dr. Scholl's^® Smooth Touch deep moisturizing cream Depicure^® So Smooth Cream Dove^® Moisturizing Cream Wash Cetaphil^ ®Moisturizing Cream Vaseline Intensive Care ^ ® lotion</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>drug/agent toxicity tissue/organ</keyword>
	<keyword>stage I breast cancer</keyword>
	<keyword>stage II breast cancer</keyword>
	<keyword>stage IIIA breast cancer</keyword>
	<keyword>stage IIIB breast cancer</keyword>
	<keyword>stage IIIC breast cancer</keyword>
	<keyword>stage IV breast cancer</keyword>
	<keyword>unspecified adult solid tumor , protocol specific</keyword>
</DOC>